Novo Nordisk announced Wednesday the upcoming U.S. launch of its oral semaglutide tablets under the Ozempic brand, with FDA approval secured for multiple doses. The move marks a significant shift for the popular diabetes treatment from injection to pill form.
As tokenization of real-world assets moves from pilot to production, Europe's unified regulatory framework under MiCA is providing the certainty needed for institutional scale. This edge could position the bloc to set global standards for the burgeoning market.
Newly released DOJ files detail communications showing Brock Pierce facilitated Epstein's entry into Coinbase's Series C round, while later emails reveal Blockchain Capital's attempts to buy his stake years later.
Amazon's acquisition of a documentary on the sitting First Lady has sparked debate over corporate influence, while analysts see potential long-term benefits far exceeding its box office performance.
A Democratic blockade of a key Federal Reserve nominee, citing ongoing investigations into sitting officials, has increased the likelihood that Chair Jerome Powell remains in his role past May. The departure of a top White House economic adviser further distances the administration from the central bank.
The Dallas-based engineering giant posted a dramatic turnaround to profit in its latest quarter, crediting a booming pipeline of AI-driven data center and semiconductor projects alongside strong water sector demand.
Varo Bank has closed a $123.9 million Series G round led by Warburg Pincus and Coliseum Capital, while adding seasoned executives from Morgan Stanley and JPMorgan Chase to its board as it navigates growth amid ongoing losses.
The Pan American Health Organization urges heightened surveillance and vaccination efforts as confirmed measles cases surge dramatically across the region, reversing years of progress.
A major human rights review accuses the Labour government of eroding civil liberties through expansive surveillance, restrictive protest laws, and the controversial banning of activist groups, raising alarms about the state of democracy in Britain.
Alex Saab, a close ally of President Nicolás Maduro and former Venezuelan minister, has been arrested in Caracas according to Colombian media reports, just months after his high-profile release from U.S. custody in a prisoner exchange deal.
The White House has deleted and corrected a social media post that falsely accused a Honduran man of child sex offenses, marking another incident of erroneous information being disseminated amid its immigration enforcement publicity campaign.
As reproductive rights face escalating legal threats, personal finance experts are advising clients to prioritize dedicated savings for abortion access—a stark reflection of America's shifting healthcare landscape.
Enphase Energy's latest quarterly results and bullish 2026 outlook have reignited investor interest, sparking a sharp rally. However, the microinverter leader's path forward is clouded by sector headwinds and a stark contrast between recent gains and steep annual losses.
Visa shares have retreated from recent highs, presenting a conundrum for investors. While its long-term track record remains stellar, short-term weakness and conflicting valuation signals demand a closer look at the payments giant's prospects.
The parent company of Titleist and FootJoy has seen its fair value estimate rise modestly to around $87, reflecting a cautious but growing confidence in its ability to meet expectations, even as some analysts warn the stock may be nearing fair price.
Super Micro Computer's stellar Q2 earnings, fueled by AI server demand, have prompted a raised annual outlook to over $40 billion. Yet, the celebration is tempered by stark realities: margins are razor-thin, and the company's fortunes are increasingly tied to one massive data center customer, reshaping its risk profile for investors.
As AutoZone's fair value estimate adjusts to around $4,210, a nuanced tug-of-war emerges on Wall Street. Analysts are fine-tuning models, balancing long-term operational confidence against near-term consumer spending concerns, reshaping the investment narrative for the auto parts retailer.
Merck & Co. posted strong 2025 sales but offered a 2026 revenue forecast below Wall Street's expectations. Despite this, its shares have rallied sharply over the past year, leading analysts to question whether the market is pricing in future pipeline success or overlooking near-term headwinds.
Analysts have nudged Teva Pharmaceutical's fair value estimate upward but tightened their valuation ranges, reflecting a guarded optimism as the company's pipeline developments through 2026 face scrutiny against a modest revenue growth forecast.
NGL Energy Partners (NGL) reported robust quarterly results, featuring record water disposal volumes and significant adjusted EBITDA growth. The partnership's units have surged over 20% in the past month, prompting investors to question if the stock still holds value after its impressive run.
